Invention Grant
- Patent Title: Anti-CD25 for tumour specific cell depletion
-
Application No.: US16979929Application Date: 2019-03-13
-
Publication No.: US11802161B2Publication Date: 2023-10-31
- Inventor: Anne Goubier , Beatriz Goyenechea Corzo , Josephine Salimu , Kevin Moulder , Pascal Merchiers , Mark Brown , James Geoghegan , Bianka Prinz , Sergio Quezada
- Applicant: Tusk Therapeutics Ltd. , Cancer Research Technology Limited
- Applicant Address: GB Hertfordshire
- Assignee: Tusk Therapeutics Ltd.,Cancer Research Technology Limited
- Current Assignee: Tusk Therapeutics Ltd.,Cancer Research Technology Limited
- Current Assignee Address: GB Hertfordshire; GB London
- Agency: Choate, Hall & Stewart LLP
- Agent Brenda Herschbach Jarrell; Michael L. Vetter
- Priority: GB 04027 2018.03.13 GB 04028 2018.03.13 GB 04029 2018.03.13 WO TEP2018056321 2018.03.13
- International Application: PCT/EP2019/056247 2019.03.13
- International Announcement: WO2019/175215A 2019.09.19
- Date entered country: 2020-09-11
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61P35/02 ; C12N15/85 ; A61P35/00 ; A61K39/395 ; C07K14/55 ; A61K45/06 ; A61K39/00
Abstract:
The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-634 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.
Public/Granted literature
- US20210009702A1 ANTI-CD25 FOR TUMOUR SPECIFIC CELL DEPLETION Public/Granted day:2021-01-14
Information query
